<DOC>
	<DOCNO>NCT02290028</DOCNO>
	<brief_summary>The QP ExCELs study design confirm safety efficacy BIOTRONIK Sentus OTW QP leave ventricular lead satisfy FDA requirement regulatory approval lead US . Long-term safety BIOTRONIK Sentus OTW QP leave ventricular lead confirm post approval phase ( US sit ) .</brief_summary>
	<brief_title>Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Standard CRTD indication accord clinical routine De novo implantation upgrade exist ICD pacemaker implant ( prior attempt LV lead placement ) utilize BIOTRONIK CRTD system IS4 LV port Sentus QP LV lead Patient able understand nature clinical investigation provide write informed consent Patient able willing complete routine study visit investigational site Patient accept Home Monitoring® concept Age ≥ 18 year Contraindication CRTD therapy Currently implant endocardial epicardial leave ventricular lead prior attempt place leave ventricular lead Cardiac surgical procedure , coronary artery bypass graft , valve surgery , ablation plan occur within 6 month implant ( ablation plan occur prior implant exclusionary ) Expected receive heart transplant ventricular assist device within 6 month Life expectancy le 12 month Participation investigational cardiac clinical investigation course study Presence another lifethreatening , underlie illness separate cardiac disorder Pregnant breastfeeding time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>CRT-D therapy</keyword>
	<keyword>quadripolar leave ventricular lead</keyword>
</DOC>